The FDA Approval of essential thrombocythemia (ET) continues to evolve as researchers investigate therapies that can address both blood-count control and the underlying biology of myeloproliferative neoplasms (MPNs). One of the most significant recent developments is the growing evidence surrounding ropeginterferon alfa-2b and its use in patients with essential thrombocythemia. The SURPASS-ET study compared ropeginterferon…
